Business
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug
About this update from Quince Therapeutics, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nQuince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2024.\n\n\nDirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Our primary corporate objective is the advancement of our lead asset, EryDex, for the treatment of patients with ataxia-telangiectasia. We remain on track to begin enrollment of our pivotal Phase 3 study in the second quarter of 2024 and will diligently pursue enrollment at U.S. and European study sites to provide an opportunity for patients living with this rare, devastating disease to participate in research to identify a beneficial therapeutic solution.\n\n\n“We are pleased to report the selection of Duchenne muscular dystrophy (DMD) as Quince’s second development program for EryDex. We consider DMD a promising indication for EryDex as corticosteroids are the standard of care for this rare disease, but its utility is limited by significant chronic toxicity due to adrenal suppression. We believe EryDex has the potential to provide the therapeutic benefit of corticosteroids without this chronic toxicity. Physicians caring for patients with DMD, along with DMD advocacy groups, also have encouraged the development of EryDex for DMD as a potentially safer alternative to conventional corticosteroids for their patients,” concluded Dr. Thye.\n\n\nPivotal Phase 3 NEAT Clinical Trial\n\n\n\nSecured regulatory approvals in the U.S. and European Union related to the company’s pivotal Phase 3 NEAT (Neurologic Effects of EryDex on Subjects with A-T; IEDAT-04-2022/NCT06193200) clinical trial.\n\n\n\n\nCommenced NEAT study site initiation and activation activities throughout the U.S., U.K., and European Union as NEAT enrollment remains on track to begin in the second quarter of 2024.\n\n\n\n\nNEAT is an international, multi-center, randomized, double-blind, placebo-controlled study to evaluate the neurological effects of the company’s lead asset, EryDex (dexamethasone sodium phosphate [DSP] encapsulated in autologous red blood cells), in patients with A-T.\n\n\n\n\...